Mehra Golshan
Yale University
196 Papers
737 Citations
Mehra Golshan is an academic researcher from Yale University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 39, co-authored 186 publications. Previous affiliations of Mehra Golshan include Northwestern University & University of Illinois at Chicago.
Chat about Author
Papers
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov,Donald A. Berry,Charles M. Perou,Baljit Singh,Constance Cirrincione,Sara M. Tolaney,Charles S. Kuzma,Timothy J. Pluard,George Somlo,Elisa Port,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Lisa A. Carey,Clifford A. Hudis,Eric P. Winer +16 more
TL;DR: In stage II to III TNBC, addition of either carboplatin or bevacizumab to NACT increased pCR rates, but whether this will improve relapse-free or overall survival is unknown.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl,Joyce O'Shaughnessy,Michael Untch,William M. Sikov,Hope S. Rugo,Mark D. McKee,Jens Huober,Mehra Golshan,Gunter von Minckwitz,David Maag,Danielle Sullivan,Norman Wolmark,Kristi McIntyre,Jose Juan Ponce Lorenzo,Otto Metzger Filho,Priya Rastogi,W. Fraser Symmans,Xuan Liu,Charles E. Geyer +18 more
TL;DR: The proportion of patients who achieved a pathological complete response in breast and lymph nodes as determined by site pathologists following completion of neoadjuvant therapy was higher in the paclitaxel, carboplatin, and veliparib group than in patients receiving pac litaxel alone.
682
Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
Stephanie M. Wong,Rachel A. Freedman,Yasuaki Sagara,Fatih Aydogan,William T. Barry,Mehra Golshan +5 more
TL;DR: The use of CPM more than tripled during the study period despite evidence suggesting no survival benefit over breast conservation, and further examination on how to optimally counsel women about surgical options is warranted.
287
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M. Tolaney,Yves Boucher,Dan G. Duda,John D. Martin,John D. Martin,Giorgio Seano,Marek Ancukiewicz,William T. Barry,Shom Goel,Johanna Lahdenrata,Steven J. Isakoff,Eren D. Yeh,Saloni R. Jain,Saloni R. Jain,Mehra Golshan,Jane E. Brock,Matija Snuderl,Eric P. Winer,Ian E. Krop,Rakesh K. Jain +19 more
TL;DR: The results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density, and suggests that new therapies are needed to normalize vessels without pruning.
247
Matched pair analyses of stage IV breast cancer with or without resection of primary breast site.
TL;DR: Case selection bias in primary breast cancer resection in state IV patients may explain most, if not all, the apparent survival advantage of such surgery.
186